Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Brenntag supervisory board member Dr. Claudine Mollenkopf buys shares worth EUR 21,540

Brenntag supervisory board member Dr. Claudine Mollenkopf buys shares worth EUR 21,540

BitgetBitget2026/10/06 13:11

Brenntag supervisory board member Dr. Claudine Mollenkopf bought shares on Oct. 6, 2026. Trades priced at EUR 59.7, volume EUR 11,940; EUR 60, volume EUR 9,600. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brenntag SE published the original content used to generate this news brief via EQS News (Ref. ID: dd_107390_de) on October 06, 2026, and is solely responsible for the information contained therein.

  • Brenntag supervisory board member Dr. Claudine Mollenkopf bought shares on Oct. 6, 2026.
  • Trades priced at EUR 59.7, volume EUR 11,940; EUR 60, volume EUR 9,600.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brenntag SE published the original content used to generate this news brief via EQS News (Ref. ID: dd_107390_de) on October 06, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials

Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.

智通财经•2026/10/10 06:21